Addition of or switch to insulin therapy in people treated with glucagon‐like peptide‐1 receptor agonists: A real‐world study in 66 583 patients
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Background: Real world outcomes of addition or switch to insulin therapy in type 2 diabetes (T2DM) patients on glucagon‐like paptide‐1 receptor agonist (GLP‐1RA) with inadequately controlled hyperglycaemia, are not known. Materials and methods: Patients with T2DM (n = 66 583) with a minimum of 6 months of GLP‐1RA treatment and without previous insulin treatment were selected. Those who added insulin (n = 39 599) or switched to insulin after GLP‐1RA cessation (n = 4706) were identified. Adjusted changes in glycated haemoglobin ( HbA1c ), weight, systolic blood pressure ( SBP ), and LDL cholesterol were estimated over 24 months follow‐up. Results: Among those who continued with GLP‐1RA treatment without adding or switching to insulin, the highest adjusted mean HbA1c change was achieved within 6 months, with no further glycaemic benefits observed during 24 months of follow‐up. Addition of insulin within 6 months of GLP‐1RA initiation was associated with 18% higher odds of achieving HbA1c <7% at 24 months, compared with adding insulin later. At 24 months, those who added insulin reduced HbA1c significantly by 0.55%, while no glycaemic benefit was observed in those who switched to insulin. Irrespective of intensification with insulin, weight, SBP and LDL cholesterol were significantly reduced by 3 kg, 3 mm Hg, and 0.2 mmol/L, respectively, over 24 months. Conclusions: Significant delay in intensification of treatment by addition of insulin is observed in patients with T2DM inadequately controlled with GLP‐1RA . Earlier addition of insulin is associated with better glycaemic control, while switching to insulin is not clinically beneficial during 2 years of treatment. Non‐responding patients on GLP‐1RA would benefit from adding insulin therapy, rather than switching to insulin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066 · cited 3×
“Micro-albuminuria, n (%) 3404 (26) 2126 (25) 1278 (29) 2481 (26) 167 (26) Macro-albuminuria, n (%) 858 (7) 532 (6) 326 (7) 597 (6) 49 (8) Hypertension, n (%) 17 415 (26) 12 707 (29) 4708 (21) 11 020 (28) 1340 (28) Metformin taken during the GLP-1RA treatment, n (%) 56 035 (84) 37 645 (85) 18 390 (83) 33 837 (85) 4129…”
Intensive glucose control and macrovascular outcomes in type 2 diabetes
Turnbull, F. M., Abraira, C., Anderson, R. J., Byington, R. P., Chalmers, J. P., Duckworth, W. C., Evans, G. W., Gerstein, H. C., Holman, R. R., Moritz, T. E., et al. (2009) · Diabetologia · doi:10.1007/s00125-009-1470-0 · Cited by 1,189 · cited 6×
“Asian 534 (1) 326 (1) 208 (1) 312 (1) 30 (1) HbA1c at diagnosis of diabetes, % 8 (1.”
BackgroundMethodInfluentialSelf-citationFox, C. S., Golden, S. H., Anderson, C., Bray, G. A., Burke, L. E., de Boer, I. H., Deedwania, P., Eckel, R. H., Ershow, A. G., Fradkin, J., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000230 · Cited by 386 · cited 5×
“Ethnicity, n (%) White 45 291 (68) 29 500 (66) 15 791 (72) 27 231 (69) 3311 (70) Black 5021 (8) 3118 (7) 1903 (9) 2971 (8) 358 (8) Hispanic 1465 (2) 943 (2) 522 (2) 1023 (3) 89 (2)”
BackgroundMethodInfluentialFactors associated with weight gain in people with type 2 diabetes starting on insulin
Balkau, B., Home, P. D., Vincent, M., Marre, M., & Freemantle, N. (2014) · Diabetes Care · doi:10.2337/dc13-3010 · Cited by 77
Novel GLP-1 receptor agonists for diabetes
Garber, A. J. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.638282 · Cited by 69 · cited 4×
“37 mmol/L at GLP-1RA initiation, n (%) 5780 (9) 3951 (9) 1829 (8) 3652 (9) 450 (10)”
Influential
Cited by
Montvida, O., Shaw, J., Atherton, J. J., Stringer, F., & Paul, S. K. (2018) · Diabetes Care · doi:10.2337/dc17-1414 · Cited by 250
Self-citationLandgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H., Müller-Wieland, D., Nauck, M. A., Reuter, H.-M., & Siegel, E. (2019) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1018-9106 · Cited by 62
Maiorino, M. I., Chiodini, P., Bellastella, G., Scappaticcio, L., Longo, M., Esposito, K., & Giugliano, D. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13343 · Cited by 52
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H., Müller-Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. (2022) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1624-3449 · Cited by 12
Metadata
- Authors
- Montvida, O., Klein, K., Kumar, S., Khunti, K., & Paul, S. K.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2016-10-18
- Volume
- 19
- Issue
- 1
- Pages
- 108-117
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2522460599
- Cited by
- 43
- References
- 5
- FWCI
- 4.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.